1.Diabetic Retinopathy Risk Factors: Plasma Erythropoietin as a Risk Factor for Proliferative Diabetic Retinopathy.
Yaghoobi GHOLAMHOSSEIN ; Heydari BEHROUZ ; Zarban ASGHAR
Korean Journal of Ophthalmology 2014;28(5):373-378
PURPOSE: The purpose of this study was to evaluate whether any stage of diabetic retinopathy (DR) is associated with levels of plasma erythropoietin and other plasma parameters. METHODS: It was examined a representative sample of 180 type 2 diabetes patients aged 40 to 79 years. Ophthalmic examination including a funduscopic examination, performed by an experienced ophthalmologist and the retinal finding were classified according to the grading system for diabetic retinopathy of ETDRS (Early Treatment Diabetic Retinopathy Study). It was measured the levels of plasma erythropoietin, cholesterol, triglyceride, apolipoproteins A and B, C-reactive protein, fasting blood glucose and hemoglobin A1C (HbA1C) in 88 DR patients and 92 controls without DR. Risk factors correlated with DR were compared between groups. RESULTS: The study group of 180 patients included 72 males and 108 females. The mean age of the patients with and without DR was 57.36 ± 8.87 years and 55.33 ± 8.28 years, respectively. Of the 88 patients with DR, only 9 (10%) had proliferative DR and the rest suffered from non-proliferative DR. The mean plasma levels of erythropoietin in proliferative DR group showed a significant difference in comparison to other groups. The mean plasma levels of cholesterol, triglyceride, apolipoproteins A and B, C-reactive protein, and fasting blood glucose were not significantly different in the three groups except for HbA1C. The absolute relative risk (ARR) also showed that erythropoietin was an increasing risk for proliferative DR (ARR, 1.17; 95% confidence interval, 1.060 to 1.420; odds ratio,1.060). CONCLUSIONS: Of the factors studied, erythropoietin level showed significant increase in proliferative DR group. The stepwise raised in mean plasma erythropoietin level which demonstrates significant correlation with proliferative DR versus remaining two groups, will be an indication of its role in proliferative DR.
Adult
;
Aged
;
Blood Glucose/metabolism
;
Cholesterol/blood
;
Cross-Sectional Studies
;
Diabetes Mellitus, Type 2/complications
;
Diabetic Retinopathy/*blood/diagnosis/*epidemiology
;
Enzyme-Linked Immunosorbent Assay
;
Erythropoietin/*blood
;
Female
;
Fluorescein Angiography
;
Hemoglobin A, Glycosylated/metabolism
;
Humans
;
Male
;
Middle Aged
;
Risk Factors
2.Factors Associated with Diabetic Retinopathy and Nephropathy Screening in Korea: The Third and Fourth Korea National Health and Nutrition Examination Survey (KNHANES III and IV).
Tyler Hyung Taek RIM ; Il Hwan BYUN ; Han Sang KIM ; Sang Yeul LEE ; Jin Sook YOON
Journal of Korean Medical Science 2013;28(6):814-820
This cross-sectional study was done to identify and determine the socio-demographic and health-related factors associated with diabetic retinopathy and nephropathy screening in Korea. Participants included 2,660 adults, aged 40 or older, with diabetes. Of the 2,660 adults, 998 (37%) and 1,226 (46.1%) had received a diabetic retinopathy and a nephropathy screening within one year, respectively. Regarding retinopathy, subjects older than 65, living in urban areas, with high educational levels, and with self-reported "unhealthy" status were likely to receive annual screening. Subjects living in urban areas, with higher educational levels, with self-reported "fair" or "unhealthy" status, and with 1 to 2 co-morbidities were likely to receive annual nephropathy screening. The Korea Composite Stock Price Index (KOSPI) continued to rise until 2007 when it started to decline over the subsequent years, following the same curve as the diabetic retinopathy and nephropathy screening rates during that time. Together with the financial matter, lack of patient education proved to be a hindrance to diabetes-related screening. The relatively low screening rates in Korea compared to the Western countries are likely to be due to the difference in the health system, economic situations and national demographics.
Adult
;
Aged
;
Cross-Sectional Studies
;
Diabetes Complications/pathology
;
Diabetes Mellitus/diagnosis
;
Diabetic Nephropathies/diagnosis/*etiology
;
Diabetic Retinopathy/diagnosis/*etiology
;
Female
;
Health Behavior
;
Health Status
;
Humans
;
Male
;
Mass Screening
;
Middle Aged
;
Nutrition Surveys
;
Odds Ratio
;
Republic of Korea
;
Risk Factors
;
Severity of Illness Index
3.The Clinical Measures Associated with C-peptide Decline in Patients with Type 1 Diabetes over 15 Years.
Tae Ho LEE ; Ah Reum KWON ; Ye Jin KIM ; Hyun Wook CHAE ; Ho Seong KIM ; Duk Hee KIM
Journal of Korean Medical Science 2013;28(9):1340-1344
This study was done to characterize the natural course of C-peptide levels in patients with type 1 diabetes and identify distinguishing characters among patients with lower rates of C-peptide decline. A sample of 95 children with type 1 diabetes was analyzed to retrospectively track serum levels of C-peptide, HbA1c, weight, BMI, and diabetic complications for the 15 yr after diagnosis. The clinical characteristics were compared between the patients with low and high C-peptide levels, respectively. The average C-peptide level among all patients was significantly reduced five years after diagnosis (P < 0.001). The incidence of diabetic ketoacidosis was significantly lower among the patients with high levels of C-peptide (P = 0.038). The body weight and BMI standard deviation scores (SDS) 15 yr after diagnosis were significantly higher among the patients with low C-peptide levels (weight SDS, P = 0.012; BMI SDS, P = 0.044). In conclusion, C-peptide level was significantly decreased after 5 yr from diagnosis. Type 1 diabetes patients whose beta-cell functions were preserved might have low incidence of diabetic ketoacidosis. The declines of C-peptide level after diagnosis in type 1 diabetes may be associated with changes of body weight and BMI.
Adolescent
;
Body Mass Index
;
Body Weight
;
C-Peptide/*blood
;
Child
;
Child, Preschool
;
Diabetes Complications
;
Diabetes Mellitus, Type 1/blood/*diagnosis
;
Diabetic Ketoacidosis/epidemiology
;
Diabetic Retinopathy/epidemiology
;
Female
;
Follow-Up Studies
;
Hemoglobin A, Glycosylated/analysis
;
Humans
;
Incidence
;
Infant
;
Male
;
Peripheral Nervous System Diseases/epidemiology
;
Retrospective Studies
4.The Degree of Diabetic Retinopathy in Patients with Type 2 Diabetes Correlates with the Presence and Severity of Coronary Heart Disease.
Taewoong UM ; Dong Hoon LEE ; Joon Won KANG ; Eun Young KIM ; Young Hee YOON
Journal of Korean Medical Science 2016;31(8):1292-1299
Both diabetic retinopathy (DR) and coronary heart disease (CHD) are clinically significant in diabetic patients. We investigated the correlation between the severity of DR and the presence and severity of CHD among type 2 diabetic patients. A total of 175 patients who were examined at the DR clinic and underwent dual-source computed tomography (DSCT) angiography within 6 months were included. The degree of DR was graded as no DR, nonproliferative DR (NPDR), and proliferative DR (PDR). The severity of CHD and the numbers of significant stenotic coronary artery on DSCT angiography according to DR grade were assessed. The mean Agatston Calcium Score (ACS) in patients with PDR was significantly higher than other groups (P < 0.001). The overall odds of an ACS increase were about 4.7-fold higher in PDR group than in no DR group (P < 0.001). In PDR group, in comparison with in no DR, the odds of having 1 or 2 arterial involvement were 3-fold higher (P = 0.044), and those of having 3 were 17-fold higher (P = 0.011). The c-index, one of the predictability values in regression analysis model, was not significantly increased when PDR was added to classical CHD risk factors (0.671 to 0.706, P = 0.111). Conclusively, patients with PDR develop a greater likelihood of not only having CHD, but being more severe nature. PDR has no additional effect to classical CHD risk factors for predicting CHD.
Aged
;
Angiography
;
Coronary Artery Disease/complications/*pathology
;
Coronary Vessels/diagnostic imaging
;
Diabetes Mellitus, Type 2/*complications
;
Diabetic Retinopathy/complications/*diagnosis/diagnostic imaging
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Linear Models
;
Male
;
Middle Aged
;
Odds Ratio
;
Risk Factors
;
Severity of Illness Index
;
Tomography, X-Ray Computed
5.The Degree of Diabetic Retinopathy in Patients with Type 2 Diabetes Correlates with the Presence and Severity of Coronary Heart Disease.
Taewoong UM ; Dong Hoon LEE ; Joon Won KANG ; Eun Young KIM ; Young Hee YOON
Journal of Korean Medical Science 2016;31(8):1292-1299
Both diabetic retinopathy (DR) and coronary heart disease (CHD) are clinically significant in diabetic patients. We investigated the correlation between the severity of DR and the presence and severity of CHD among type 2 diabetic patients. A total of 175 patients who were examined at the DR clinic and underwent dual-source computed tomography (DSCT) angiography within 6 months were included. The degree of DR was graded as no DR, nonproliferative DR (NPDR), and proliferative DR (PDR). The severity of CHD and the numbers of significant stenotic coronary artery on DSCT angiography according to DR grade were assessed. The mean Agatston Calcium Score (ACS) in patients with PDR was significantly higher than other groups (P < 0.001). The overall odds of an ACS increase were about 4.7-fold higher in PDR group than in no DR group (P < 0.001). In PDR group, in comparison with in no DR, the odds of having 1 or 2 arterial involvement were 3-fold higher (P = 0.044), and those of having 3 were 17-fold higher (P = 0.011). The c-index, one of the predictability values in regression analysis model, was not significantly increased when PDR was added to classical CHD risk factors (0.671 to 0.706, P = 0.111). Conclusively, patients with PDR develop a greater likelihood of not only having CHD, but being more severe nature. PDR has no additional effect to classical CHD risk factors for predicting CHD.
Aged
;
Angiography
;
Coronary Artery Disease/complications/*pathology
;
Coronary Vessels/diagnostic imaging
;
Diabetes Mellitus, Type 2/*complications
;
Diabetic Retinopathy/complications/*diagnosis/diagnostic imaging
;
Female
;
Glomerular Filtration Rate
;
Humans
;
Linear Models
;
Male
;
Middle Aged
;
Odds Ratio
;
Risk Factors
;
Severity of Illness Index
;
Tomography, X-Ray Computed
6.Efficacy of Intravitreal Triamcinolone Acetonide for Eyes with Postvitrectomy Diabetic Vitreous Hemorrhage.
Sun Young LEE ; Hee Gyung LEE ; Hyewon CHUNG ; Young Hee YOON ; June Gone KIM
Korean Journal of Ophthalmology 2007;21(4):208-212
PURPOSE: To evaluate the efficacy of intravitreal triamcinolone acetonide (IVT) for the management of postvitrectomy diabetic vitreous hemorrhage. METHODS: The authors conducted a retrospective study of patients with postvitrectomy diabetic vitreous hemorrhage who were administered 4 mg (0.1 cc) of triamcinolone acetonide ophthalmic suspension. Ocular history, adverse events, BCVA, intraocular pressure, external eye examination, slit-lamp biomicroscopy, fundus examination, B-scan ultrasonography, and fundus photography were assessed on day 1, weeks 1, 2, and 4 and months 2 and 3. RESULTS: There were 19 eyes of 18 consecutive patients with mean follow-up after IVT injection of 28 weeks. Of the 19 eyes, 17 eyes (89%) experienced clearing of vitreous hemorrhage within 1 to 5 weeks (mean, 1.7 weeks) with visible triamcinolone precipitates along with blood clot in the inferior aspect of fundus. Of these 17 eyes, 12 eyes (63%) maintained vitreous hemorrhage-free condition at last follow-up with a mean visual acuity of 20/63 (range, 20/320 20/25), whereas 5 (29%) developed recurrent vitreous hemorrhage after clearing of vitreous hemorrhage. Vitreous hemorrhage was not cleared in 2 eyes, which required surgical procedures. CONCLUSIONS: IVT injection may be beneficial for clearing recurrent postvitrectomy Diabetic Vitreous Hemorrhage.
Adult
;
Aged
;
Diabetic Retinopathy/*complications/diagnosis
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Postoperative Hemorrhage/diagnosis/*drug therapy/etiology
;
Retrospective Studies
;
Time Factors
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitrectomy/*adverse effects
;
Vitreous Body
;
Vitreous Hemorrhage/diagnosis/*drug therapy/etiology
7.Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema.
Soo Jeong LEE ; Ei Tae KIM ; Yeon Sung MOON
Korean Journal of Ophthalmology 2011;25(5):299-304
PURPOSE: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. METHODS: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. RESULTS: In patients with the bevacizumab injection only, VA improved from 0.29 +/- 0.18 to 0.48 +/- 0.26 at 1 month and returned to 0.32 +/- 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 +/- 0.22 to 0.52 +/- 0.26 at 1 month and returned to 0.36 +/- 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow-up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. CONCLUSIONS: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Diabetic Retinopathy/*complications/diagnosis/therapy
;
Dose-Response Relationship, Drug
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
8.Intravitreal Bevacizumab Alone versus Combined with Macular Photocoagulation in Diabetic Macular Edema.
Soo Jeong LEE ; Ei Tae KIM ; Yeon Sung MOON
Korean Journal of Ophthalmology 2011;25(5):299-304
PURPOSE: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type were researched using optical coherence tomography. METHODS: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morphologic pattern was compared. RESULTS: In patients with the bevacizumab injection only, VA improved from 0.29 +/- 0.18 to 0.48 +/- 0.26 at 1 month and returned to 0.32 +/- 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 +/- 0.22 to 0.52 +/- 0.26 at 1 month and returned to 0.36 +/- 0.18 at 6 months after treatment. There was no significant improvement of VA at the final follow-up with either treatment. There was significant decrease of macular thickness except in the mixed DME type. CONCLUSIONS: The combination treatment did not yield better VA or macular thickness reduction at 6 months than bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment objectively and predicting the effectiveness of treatment can be helpful.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Diabetic Retinopathy/*complications/diagnosis/therapy
;
Dose-Response Relationship, Drug
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation/*methods
;
Macular Edema/diagnosis/etiology/*therapy
;
Male
;
Microscopy, Acoustic
;
Middle Aged
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
9.Dose Dependent Effects of Intravitreal Triamcinolone Acetonide on Diffuse Diabetic Macular Edema.
Joon Sung BAE ; Sung Joon PARK ; I Rum HAM ; Tae Gon LEE
Korean Journal of Ophthalmology 2009;23(2):80-85
PURPOSE: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. METHODS: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 mg (n=12 eyes), 8 mg (n=17) or 25 mg (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. RESULTS: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. CONCLUSIONS: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg.
Adult
;
Aged
;
Aged, 80 and over
;
Diabetic Retinopathy/*complications/drug therapy/pathology
;
Dose-Response Relationship, Drug
;
Female
;
Follow-Up Studies
;
Glucocorticoids/*administration & dosage
;
Humans
;
Injections
;
Intraocular Pressure
;
Macular Edema/diagnosis/*drug therapy/etiology
;
Male
;
Middle Aged
;
Retrospective Studies
;
Time Factors
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Triamcinolone Acetonide/*administration & dosage
;
Visual Acuity
;
Vitreous Body